← The Wire
VYGRNasdaq
Voyager Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · DE · CIK 1640266
Leveraging human genetics to cure neurological diseases with gene therapies and antibodies
red 8-K · 90d
$211M
Market cap
$3.58
Last close
-0.3%
1D
-3.8%
5D
657K
Volume
Price · last 39 sessions-7.7%
May 4L $3.32 · H $4.24Jun 29
197
Total filings
Jun 10, 2026
Last filing
12/31
Fiscal year end
8-KBylaw Amendment · Shareholder VoteJun 10, 20268-KCompany UpdateJun 1, 20268-KResults of OperationsMay 7, 202610-Q10-QMay 7, 2026DEFA14ADEFA14AApr 28, 2026DEF 14ADEF 14AApr 28, 20268-KExecutive ChangeApr 21, 20268-KResults of OperationsMar 9, 202610-K10-KMar 9, 20268-KExecutive Change · Company UpdateFeb 12, 20268-KReg FD DisclosureJan 8, 202610-Q10-QNov 10, 20258-KResults of OperationsNov 10, 20258-KReg FD DisclosureSep 2, 202510-Q10-QAug 6, 20258-KResults of OperationsAug 6, 20258-KExecutive Change · Shareholder VoteJun 5, 202510-Q10-QMay 6, 20258-KResults of OperationsMay 6, 2025DEFA14ADEFA14AApr 23, 2025DEF 14ADEF 14AApr 23, 202510-K10-KMar 11, 20258-KResults of OperationsMar 11, 20258-KCompany UpdateFeb 11, 202510-Q10-QNov 12, 20248-KResults of OperationsNov 12, 20248-KMaterial AgreementSep 5, 202410-Q10-QAug 6, 20248-KResults of OperationsAug 6, 20248-KExecutive ChangeJun 13, 20248-KShareholder VoteJun 6, 20248-KCompany UpdateMay 16, 202410-Q10-QMay 13, 20248-KResults of OperationsMay 13, 2024DEFA14ADEFA14AApr 25, 2024DEF 14ADEF 14AApr 25, 20248-KExecutive ChangeApr 2, 20248-KCompany UpdateMar 13, 202410-K10-KFeb 28, 20248-KResults of OperationsFeb 28, 2024SC 13GSC 13GJan 29, 20248-KMaterial Agreement · Company UpdateJan 8, 2024424B5424B5Jan 8, 2024424B5424B5Jan 4, 20248-KMaterial Agreement · Results of OperationsJan 2, 20248-KCompany UpdateDec 6, 202310-Q10-QNov 6, 20238-KResults of OperationsNov 6, 20238-KMaterial Agreement · New Debt / ObligationAug 16, 202310-Q10-QAug 3, 20238-KResults of OperationsAug 3, 20238-KCompany UpdateJul 10, 20238-KShareholder VoteJun 7, 2023DEFA14ADEFA14AMay 9, 202310-Q10-QMay 9, 20238-KResults of OperationsMay 9, 20238-KExecutive ChangeMay 9, 2023DEFA14ADEFA14AApr 27, 2023DEF 14ADEF 14AApr 27, 20238-KCompany UpdateMar 13, 202310-K10-KMar 7, 20238-KResults of OperationsMar 7, 20238-KExecutive Change · Company UpdateFeb 24, 20238-KExecutive ChangeFeb 23, 2023SC 13GSC 13GFeb 14, 20238-KMaterial Agreement · Results of OperationsJan 9, 20238-KExecutive ChangeDec 14, 202210-Q10-QNov 8, 20228-KResults of OperationsNov 8, 20228-KCompany UpdateOct 4, 20228-KExecutive Change · Company UpdateSep 7, 202210-Q10-QAug 4, 20228-KResults of OperationsAug 4, 20228-KExecutive ChangeJul 28, 20228-KMaterial Agreement · Agreement TerminatedJun 23, 20228-KExecutive Change · Shareholder VoteJun 7, 202210-Q10-QMay 4, 20228-KResults of OperationsMay 4, 2022DEFA14ADEFA14AApr 21, 2022DEF 14ADEF 14AApr 21, 2022
Insider Activity
In the 90 days to Feb 24, 2026: 4 sold $253K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 24, 2026 | Sandrock AlfredPresident and CEO | Sell | 14,197 | $3.79 | $54K |
| Feb 24, 2026 | Swartz RobinCOO & CBO | Sell | 6,458 | $3.77 | $24K |
| Feb 24, 2026 | Jorgensen Nathan D.Chief Financial Officer | Sell | 4,668 | $3.77 | $18K |
| Feb 24, 2026 | Carter Todd AlfredChief Scientific Officer | Sell | 4,174 | $3.76 | $16K |
| Feb 18, 2026 | Sandrock AlfredPresident and CEO | Sell | 11,732 | $3.41 | $40K |
| Feb 18, 2026 | Swartz RobinCOO & CBO | Sell | 3,882 | $3.44 | $13K |
| Feb 18, 2026 | Carter Todd AlfredChief Scientific Officer | Sell | 3,301 | $3.44 | $11K |
| Feb 10, 2026 | Sandrock AlfredPresident and CEO | Sell | 12,192 | $3.78 | $46K |
| Feb 10, 2026 | Swartz RobinCOO & CBO | Sell | 4,569 | $3.85 | $18K |
| Feb 10, 2026 | Carter Todd AlfredChief Scientific Officer | Sell | 3,525 | $3.85 | $14K |
| Oct 3, 2025 | Jorgensen Nathan D.Chief Financial Officer | Sell | 7,666 | $4.78 | $37K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance